Sethuraman Natarajan forfeited 2,079 Entrada Therapeutics shares at $7.14 per share. After the transaction, the president of Research and Development owned 214,238 shares, giving investors the disclosed post-transaction ownership figure for the executive.

Key Highlights

  • The shares were forfeited at $7.14 per share.
  • Sethuraman Natarajan owned 214,238 shares after the transaction.
  • The transaction occurred on September 2, 2026.

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported the forfeiture of 2,079 shares by Sethuraman Natarajan, its president of research and development. The transaction took place at $7.14 per share.

Share Forfeiture at $7.14

Sethuraman Natarajan completed the share forfeiture on September 2, 2026. The filing reported 2,079 Entrada Therapeutics shares at $7.14 per share. Natarajan serves as the company’s president of research and development.

Post-Transaction Ownership

Natarajan owned 214,238 Entrada Therapeutics shares after the transaction. The filing reported this ownership following the transaction.